The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...

However, significant barriers stand in the way of realising this promise on a worldwide scale, from manufacturing costs and ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

A GROUNDBREAKING genetic treatment with the potential to cure sickle cell disease will be rolled out on the NHS. The one-off ...

MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering focused company, recently announced the acquisition of SeQure DX Inc., a market leader in on-target and off-target editing assessment services ...

Initiation of Phase 1b study using SGT-212 for the treatment of patients with Friedreich's Ataxia expected in 2H25. Click ...

January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

NDAQ:SLDB) Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia ...

There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.

In the ever-evolving field of longevity and anti-aging research, chemical sciences are making significant strides, ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...